MedDRA preferred term

Injection site warmth: adverse event reports recording this term

20,317 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

20,317
reports recording the term: 0.1% of all reports; 778
reports, 12 months to June 2026: 785 in the 12 months before; 14.3%
marked serious by the reporter: 57.4% across all reports; 0.1%
record death among outcomes, as reported: 9.1% across all reports

"Injection site warmth" is a MedDRA preferred term recorded in 20,317 adverse event reports received by FDA, 0.1% of the database, from February 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

778 reports recorded it in the 12 months to June 2026, close to the 785 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 14.3% are marked serious, 0.1% include death among the outcomes and 4.1% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Enbrel, Humira and Dupixent. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Enbrel	Tumor necrosis factor blocker	10,370	1.8%
Humira	—	2,382	0.4%
Dupixent	Interleukin-4 receptor alpha antagonist	1,066	0.2%
Taltz	Interleukin-17A antagonist	479	1.4%
Makena	—	286	1.3%
Vivitrol	—	239	1%
Copaxone	—	208	0.5%
Emgality	—	203	0.7%
Repatha	PCSK9 inhibitor	193	0.1%
Mounjaro	GLP-1 receptor agonist	179	0.2%
Strensiq	—	157	1.7%
Humira 40 Mg/0 8 Ml Pen	—	156	1%
Avonex	Interferon beta	143	0.1%
Ajovy	—	131	1.3%
Plegridy	Interferon beta	126	1%
Zepbound	GLP-1 receptor agonist	126	0.2%
Trulicity	GLP-1 receptor agonist	117	0.2%
Kineret	Interleukin-1 receptor antagonist	115	1.3%
Praluent	PCSK9 inhibitor	114	0.5%
Bydureon	—	109	0.6%
Rebif	Interferon beta	108	0.2%
Glatopa	—	104	1.7%
Kevzara	Interleukin-6 receptor antagonist	104	0.4%
Palynziq	—	91	1.1%
Cosentyx	Interleukin-17A antagonist	84	0.1%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Tumor necrosis factor blocker	10,515	1%	0%
Interleukin-4 receptor alpha antagonist	1,116	0.2%	0.3%
Interleukin-17A antagonist	577	0.3%	0.7%
GLP-1 receptor agonist	490	0.1%	0%
Interferon beta	388	0.2%	0.2%
PCSK9 inhibitor	307	0.2%	0.1%
Interleukin-6 receptor antagonist	118	0.1%	0%
Interleukin-1 receptor antagonist	117	0.8%	0.7%
Folate analog metabolic inhibitor	103	0%	0%
Anti-IgE	80	0.1%	0.1%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20%9

2 to 110.9%191

12 to 171.3%262

18 to 4424.1%4,897

45 to 6433.4%6,791

65 to 746.5%1,319

75 and over2.1%421

Age not given31.6%6,427

Patient sex

Female78.8%16,019

Male13.4%2,731

Not given7.7%1,567

Grey bar: all 20,646,523 reports in the database. 92.7% of these reports give the United States as the country.

Questions about "Injection site warmth"

What does "Injection site warmth" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record injection site warmth?

20,317 reports through June 2026 (0.1% of all reports), 778 of them in the latest 12 months.

Which drugs appear most often in these reports?

Enbrel (10,370), Humira (2,382), Dupixent (1,066), Taltz (479) and Makena (286). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.